Actively Recruiting
Biomarkers of Endometrial Receptivity
Led by The Institute of Molecular and Translational Medicine, Czech Republic · Updated on 2026-03-20
476
Participants Needed
3
Research Sites
452 weeks
Total Duration
On this page
Sponsors
T
The Institute of Molecular and Translational Medicine, Czech Republic
Lead Sponsor
U
University Hospital Olomouc
Collaborating Sponsor
AI-Summary
What this Trial Is About
Analysis of proteins from cervical mucus will be done in patients undergoing infertility treatment (fresh or frozen embryo transfer). Cervical mucus will be analysed for potential new biomarkers of endometrium receptivity. Comparison of the peptide spectrum will be done for the pregnant and not pregnant patients.
CONDITIONS
Official Title
Biomarkers of Endometrial Receptivity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female younger than 37 years (up to 36 years and 364 days)
- Non-smoker
- Regular menstrual cycles lasting 25 to 35 days
- Infertility duration less than five years
- Normal responder to fertility treatment
- Fewer than three failed assisted reproduction cycles including fresh or frozen embryo transfers
- Partner's sperm obtained through ejaculation
- Spermiogram showing more than 5 million sperm per milliliter
- Body mass index between 19 and 29 kg/m2
- Follicle stimulating hormone (FSH) less than 10 IU/L on day 3 of cycle
- Basal antral follicle count between 5 and 15
- Undergoing standard hormone stimulation or substitution protocols
- Provided informed consent
You will not qualify if you...
- Genetic diseases
- Metabolic or endocrine disorders including diabetes, metabolic syndrome, thyroid disorders, or hyperprolactinaemia
- Polycystic ovary syndrome as defined by Rotterdam criteria
- Prior diagnosis of endometriosis or adenomyosis
- Previous gynecological or pelvic surgery except salpingectomy
- Repeated spontaneous abortions (two or more)
- Previously had fewer than 5 oocytes or anti-Mullerian hormone below 1.0 mIU/ml (stimulated cycle) or below 0.5 mIU/ml (substituted cycle)
- Previous ovarian hyperstimulation syndrome (OHSS)
- Structural abnormalities of the reproductive system
- Donor oocyte cycles
- Severe male factor infertility with sperm count below 5 million per milliliter
- Low response to stimulation
- Endometrium thickness less than 8 mm at day of hCG or embryo transfer
- Number of retrieved oocytes outside 5 to 20
- Low fertilization capacity (fertilization rate below 20% or late ICSI after IVF failure)
- Cycle cancelled before embryo transfer
- Transfer other than one high-quality blastocyst (at least grade 3BB)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Brno University Hospital
Brno, South Moravian, Czechia, 62500
Actively Recruiting
2
University Hospital Olomouc
Olomouc, Czechia, 77900
Actively Recruiting
3
University Hospital Olomouc
Olomouc, Czechia
Actively Recruiting
Research Team
R
Radovan Pilka, Prof.MD.PhD.
CONTACT
P
Petr Dzubak, MD.PhD.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here